- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004497
Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension
OBJECTIVES:
I. Determine the safety and efficacy of UT-15 in patients with severe symptomatic primary pulmonary hypertension.
Study Overview
Detailed Description
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study. Patients are stratified according to center and etiology of disease.
Patients receive conventional oral therapy plus a continuous subcutaneous infusion of either UT-15 or placebo for 12 weeks.
After completing 12 weeks of treatment, patients may continue therapy with open label UT-15. Patients who received placebo cross over to receive UT-15.
Completion date provided represents the completion date of the grant per OOPD records
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Torrance, California, United States, 90509
- Los Angeles County Harbor-UCLA Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush-Presbyterian-St. Luke's Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland Medical System
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10032
- Columbia University College of Physicians and Surgeons
-
-
North Carolina
-
Research Triangle Park, North Carolina, United States, 27709
- United Therapeutics Corporation
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232-2516
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Diagnosis of moderate to severe precapillary pulmonary hypertension (New York Heart Association class III/IV) unresponsive to attempted use of chronic oral vasodilators for at least 1 month
Cardiac catheterization at baseline: Pulmonary artery pressure at least 25 mm Hg AND Pulmonary capillary wedge pressure or left ventricular end diastolic pressure no greater than 15 mm Hg AND Pulmonary vascular resistance greater than 3 mm Hg/L/min
Echocardiogram at baseline: Right ventricular hypertrophy or dilation AND Normal left ventricular function AND Absence of mitral valve stenosis
Chest radiograph within prior 3 months Clear lung fields OR Multiple patchy interstitial (not diffuse) lung fields AND At least 1 of the following:
- Right ventricular enlargement
- Prominence of main pulmonary artery
- Enlarged hilar vessels
- Decreased peripheral vessels
No significant parenchymal lung disease within prior 3 months as evidenced by: Total lung capacity no greater than 70% predicted FEV/FVC ratio no greater than 50% Diffuse interstitial fibrosis or alveolitis by high resolution CT if total lung capacity is 70-80% or DLCO less than 60%
No chronic thromboembolic disease with clot proximal to lobar bifurcation
Baseline exercise capacity at least 50 meters walked in six minutes
--Prior/Concurrent Therapy--
Endocrine therapy:
- At least 30 days since prior chronic prostaglandin or prostaglandin analogue therapy (including Flolan IV)
- No concurrent prostaglandins or prostaglandin analogues
Other:
- At least 1 month since prior new type of chronic therapy (e.g., different category of vasodilator, diuretic, digoxin) for pulmonary hypertension, except anticoagulants
- At least 1 week since discontinuation of prior pulmonary hypertension medication, except anticoagulants
- At least 30 days since prior participation in an investigational drug study
- No other concurrent investigational drug
- No concurrent chronic intravenous or inhaled medications (except oxygen)
--Patient Characteristics--
Cardiovascular:
- No portal hypertension
- No left sided heart disease as defined by: Pulmonary capillary wedge pressure or left ventricular end diastolic pressure greater than 15 mm Hg OR LVEF less than 40% by MUGA or angiography OR LV shortening fraction less than 22% by echocardiography OR Symptomatic coronary disease (demonstrable ischemia)
Other:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Mentally and physically capable of using an infusion pump
- HIV negative
- No other disease associated with pulmonary hypertension (sickle cell anemia, schistosomiasis)
- No musculoskeletal disorder (arthritis, artificial leg, etc.) or any disease limiting ambulation, or connected to a nonportable machine
- No concurrent physiological condition contraindicating use of UT-15
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Masking: Double
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: James Walker Crow, United Therapeutics
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 199/14287
- UTC-FDR001545
- UTC-P01-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Heidelberg UniversityMerck Sharp & Dohme LLCRecruitingChronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial HypertensionGermany
-
University of South FloridaWithdrawnPulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Idiopathic Pulmonary Arterial Hypertension | Primary Pulmonary HypertensionUnited States
-
BayerCompletedPrimary HypertensionChina
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
Papworth Hospital NHS Foundation TrustMerck Sharp & Dohme LLCCompleted
-
University of ZurichCompletedPulmonary Hypertension | Pulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary HypertensionSwitzerland
-
National Taiwan University HospitalUnknownPulmonary HypertensionTaiwan
Clinical Trials on UT-15
-
United TherapeuticsUniversity of Pittsburgh Medical CenterWithdrawnLiver TransplantUnited States
-
United TherapeuticsWithdrawnPulmonary HypertensionUnited States, Australia, Mexico
-
United TherapeuticsCompletedPulmonary Arterial Hypertension | Hypertension, PulmonaryUnited States
-
United TherapeuticsCompleted
-
Oncternal Therapeutics, IncRecruitingMetastatic Castration-resistant Prostate CancerUnited States, United Kingdom
-
United TherapeuticsCompletedPulmonary HypertensionUnited States, Canada, Germany, Spain, Belgium, Sweden, Israel, France, Italy, Netherlands, Portugal, United Kingdom
-
University of WashingtonNational Multiple Sclerosis SocietyCompleted
-
United TherapeuticsCompletedPulmonary Arterial Hypertension | Hypertension, PulmonaryUnited States
-
United TherapeuticsCompletedAn Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionKorea, Republic of, United States, Australia, Austria, Taiwan, China, Israel, Canada, India, Germany, Singapore, United Kingdom, Brazil, Italy, Netherlands, Argentina, Sweden, Chile, Denmark, France, Greece, Mexico, Poland